{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:38:51Z","timestamp":1791041931599,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":156,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ghir.2023.101532","type":"journal-article","created":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T09:37:22Z","timestamp":1681033042000},"page":"101532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Efficacy and safety of growth hormone therapy in children with Noonan syndrome"],"prefix":"10.1016","volume":"69-70","author":[{"given":"Giorgio","family":"Sodero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Celeste","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Malavolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Arzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/humu.20955","article-title":"Germline BRAF mutations in Noonan, LEOPARD, and cardio-facio-cutaneous syndromes: molecular diversity and associated phenotypic spectrum","volume":"30","author":"Sarkozy","year":"2009","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajmg.1320210312","article-title":"Noonan syndrome: a review","volume":"21","author":"Mendez","year":"1985","journal-title":"Am. J. Med. Genet."},{"issue":"Suppl. 2","key":"10.1016\/j.ghir.2023.101532_bb0015","first-page":"64","article-title":"Noonan syndrome, the Ras-MAPK signalling pathway and short stature","volume":"71","author":"Binder","year":"2009","journal-title":"Horm. Res."},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11154-006-9021-1","article-title":"Noonan syndrome and related disorders: alterations in growth and puberty","volume":"7","author":"Noonan","year":"2006","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0030","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0615","article-title":"Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status","volume":"11","author":"Jorge","year":"2022","journal-title":"Endocr. Connect."},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0035","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0549","article-title":"Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence","volume":"11","author":"Romano","year":"2022","journal-title":"Endocr. Connect."},{"issue":"6","key":"10.1016\/j.ghir.2023.101532_bb0040","first-page":"2291","article-title":"The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan\u2019s syndrome","volume":"81","author":"Cotterill","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000500264","article-title":"Impact of growth hormone therapy on adult height in patients with PTPN11 mutations related to Noonan syndrome","volume":"91","author":"Malaquias","year":"2019","journal-title":"Horm. Res. Paediatr."},{"issue":"5 Pt 2","key":"10.1016\/j.ghir.2023.101532_bb0050","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0022-3476(96)70005-7","article-title":"Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience","volume":"128","author":"Romano","year":"1996","journal-title":"J. Pediatr."},{"issue":"7","key":"10.1016\/j.ghir.2023.101532_bb0055","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1210\/jc.2008-2094","article-title":"Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone","volume":"94","author":"Romano","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2023.101532_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.761171","article-title":"Growth in children with Noonan syndrome and effects of growth hormone treatment on adult height","volume":"12","author":"Libraro","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.ghir.2023.101532_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF02731057","article-title":"alSalmi I, Fattah MA. Defective growth hormone (GH) secretion and short-term treatment in Noonan syndrome","volume":"65","author":"Soliman","year":"1998","journal-title":"Indian J. Pediatr."},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2001.01188.x","article-title":"Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment","volume":"54","author":"Noordam","year":"2001","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"10.1016\/j.ghir.2023.101532_bb0075","first-page":"889","article-title":"Growth hormone treatment in children with Noonan\u2019s syndrome: four year results of a partly controlled trial","volume":"90","author":"Noordam","year":"2001","journal-title":"Acta Paediatr."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-08-0413","article-title":"Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11","volume":"159","author":"Noordam","year":"2008","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.ghir.2023.101532_bb0085","first-page":"1953","article-title":"Growth hormone therapy and growth in children with Noonan\u2019s syndrome: results of 3 years\u2019 follow-up","volume":"86","author":"MacFarlane","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ghir.2023.101532_bb0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1515\/JPEM.2002.15.6.851","article-title":"Growth hormone therapy in Noonan\u2019s syndrome: non-cardiomyopathic congenital heart disease does not adversely affect growth improvement","volume":"15","author":"Brown","year":"2002","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2023.101532_bb0095","article-title":"Lack of catch-up growth with growth hormone treatment in a child born small for gestational age leading to a diagnosis of Noonan syndrome with a pathogenic PTPN11 variant","volume":"2021","author":"Olivieri","year":"2021","journal-title":"Case Rep. Endocrinol."},{"issue":"9","key":"10.1016\/j.ghir.2023.101532_bb0100","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1651-2227.2005.tb02081.x","article-title":"Improved final height with long-term growth hormone treatment in Noonan syndrome","volume":"94","author":"Osio","year":"2005","journal-title":"Acta Paediatr."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.6065\/apem.1938154.077","article-title":"Effectiveness of growth hormone therapy in children with Noonan syndrome","volume":"25","author":"Seok","year":"2020","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.ghir.2023.101532_bb0110","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1002\/ajmg.a.37260","article-title":"Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: patterns of growth, puberty and final height data","volume":"167A","author":"Tamburrino","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0115","article-title":"Progressive left ventricular outflow tract stenosis in a Noonan syndrome patient with severe hypertrophic cardiomyopathy during growth hormone treatment","volume":"14","author":"Ichikawa","year":"2022","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.6065\/apem.2016.21.1.26","article-title":"Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with Noonan syndrome","volume":"21","author":"Jeong","year":"2016","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.ghir.2023.101532_bb0125","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1651-2227.1997.tb15175.x","article-title":"Growth hormone therapy in pre-pubertal children with Noonan syndrome: first year growth response and comparison with turner syndrome","volume":"86","author":"De Schepper","year":"1997","journal-title":"Acta Paediatr."},{"issue":"5","key":"10.1016\/j.ghir.2023.101532_bb0130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/adc.84.5.440","article-title":"Short stature in Noonan syndrome: response to growth hormone therapy","volume":"84","author":"Kirk","year":"2001","journal-title":"Arch. Dis. Child."},{"issue":"6","key":"10.1016\/j.ghir.2023.101532_bb0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000339677","article-title":"Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation","volume":"77","author":"Choi","year":"2012","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.ghir.2023.101532_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.737893","article-title":"GH responsiveness in children with Noonan syndrome compared to turner syndrome","volume":"12","author":"Dahlgren","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"10","key":"10.1016\/j.ghir.2023.101532_bb0145","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1002\/ajmg.a.37191","article-title":"Improved growth velocity of a patient with Noonan-like syndrome with loose anagen hair (NS\/LAH) without growth hormone deficiency by low-dose growth hormone therapy","volume":"167A","author":"Takasawa","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"10.1016\/j.ghir.2023.101532_bb0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1507\/endocrj.EJ17-0313","article-title":"Efficacy and safety of two doses of Norditropin\u00ae (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients","volume":"65","author":"Ozono","year":"2018","journal-title":"Endocr. J."},{"issue":"7","key":"10.1016\/j.ghir.2023.101532_bb0155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3345\/kjp.2018.06842","article-title":"Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome","volume":"62","author":"Jo","year":"2019","journal-title":"Korean J. Pediatr."},{"issue":"9","key":"10.1016\/j.ghir.2023.101532_bb0160","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1210\/jc.2004-2559","article-title":"PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome","volume":"90","author":"Ferreira","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0165","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.107292","article-title":"Effect of growth hormone therapy in patients with Noonan syndrome: a retrospective study","volume":"18","author":"Apperley","year":"2020","journal-title":"Int. J. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0170","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1651-2227.1991.tb11880.x","article-title":"Noonan\u2019s syndrome: abnormalities of the growth hormone\/IGF-I axis and the response to treatment with human biosynthetic growth hormone","volume":"80","author":"Ahmed","year":"1991","journal-title":"Acta Paediatr. Scand."},{"issue":"8","key":"10.1016\/j.ghir.2023.101532_bb0175","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.medcli.2013.06.019","article-title":"Identificaci\u00f3n gen\u00e9tica de un Caso de s\u00edndrome de Noonan y tratamiento con hormona de crecimiento [genetic identification of a case of Noonan syndrome and treatment with growth hormone]","volume":"142","author":"Pi","year":"2014","journal-title":"Med. Clin. (Barc.)"},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1507\/endocrj.51.61","article-title":"Clinical evaluation of recombinant human growth hormone in Noonan syndrome","volume":"51","author":"Ogawa","year":"2004","journal-title":"Endocr. J."},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0185","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000498859","article-title":"Treatment with growth hormone in Noonan syndrome observed during 25 years of KIGS: near adult height and outcome prediction","volume":"91","author":"Ranke","year":"2019","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.ghir.2023.101532_bb0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13052-015-0183-x","article-title":"Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency","volume":"41","author":"Zavras","year":"2015","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ghir.2023.101532_bb0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/JPEM.2002.15.2.175","article-title":"The relationship between clinical severity of Noonan\u2019s syndrome and growth, growth hormone (GH) secretion and response to GH treatment","volume":"15","author":"Noordam","year":"2002","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1687-9856-2012-15","article-title":"Effect of 4years of growth hormone therapy in children with Noonan syndrome in the American Norditropin studies: web-enabled research (ANSWER) program\u00ae registry","volume":"2012","author":"Lee","year":"2012","journal-title":"Int. J. Pediatr. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13633-015-0015-1","article-title":"Noonan syndrome and turner syndrome patients respond similarly to 4 years\u2019 growth-hormone therapy: longitudinal analysis of growth-hormone-na\u00efve patients enrolled in the NordiNet\u00ae international outcome study and the ANSWER program","volume":"2015","author":"Lee","year":"2015","journal-title":"Int. J. Pediatr. Endocrinol."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/JPEM.2008.21.3.267","article-title":"Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database","volume":"21","author":"Raaijmakers","year":"2008","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ghir.2023.101532_bb0215","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1507\/endocrj.EJ19-0371","article-title":"Long-term efficacy and safety of two doses of Norditropin\u00ae (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients","volume":"67","author":"Horikawa","year":"2020","journal-title":"Endocr. J."},{"issue":"5","key":"10.1016\/j.ghir.2023.101532_bb0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF03346324","article-title":"Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance","volume":"30","author":"Walton-Betancourth","year":"2007","journal-title":"J. Endocrinol. Investig."},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0225","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4274\/jcrpe.galenos.2022.2022-12-13","article-title":"The effect of growth hormone therapy on cardiac outcomes in Noonan syndrome: long term follow-up results","volume":"14","author":"K\u0131z\u0131lcan \u00c7etin","year":"2022","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"6","key":"10.1016\/j.ghir.2023.101532_bb0230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000512429","article-title":"Long-term effectiveness and safety of childhood growth hormone treatment in Noonan syndrome","volume":"93","author":"Rohrer","year":"2020","journal-title":"Horm. Res. Paediatr."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0235","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4274\/jcrpe.3013","article-title":"The growth characteristics of patients with Noonan syndrome: results of three years of growth hormone treatment: a nationwide multicenter study","volume":"8","author":"\u015e\u0131klar","year":"2016","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"8","key":"10.1016\/j.ghir.2023.101532_bb0240","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ajmg.a.61638","article-title":"A case report of Noonan syndrome-like disorder with loose anagen hair 2 treated with recombinant human growth hormone","volume":"182","author":"Zhou","year":"2020","journal-title":"Am. J. Med. Genet. A"},{"issue":"5","key":"10.1016\/j.ghir.2023.101532_bb0245","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1530\/eje.0.1510567","article-title":"Early treatment with GH alone in turner syndrome: prepubertal catch-up growth and waning effect","volume":"151","author":"Wasniewska","year":"2004","journal-title":"Eur. J. Endocrinol."},{"issue":"Suppl","key":"10.1016\/j.ghir.2023.101532_bb0250","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1507\/endocrj.47.SupplMarch_S115","article-title":"Bone mineral density in turner syndrome: relation to GH treatment and estrogen treatment","volume":"47","author":"Sato","year":"2000","journal-title":"Endocr. J."},{"issue":"6","key":"10.1016\/j.ghir.2023.101532_bb0255","article-title":"2011 Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome","volume":"98","author":"Deal","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2023.101532_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2022.101522","article-title":"Growth hormone responses during arginine and clonidine stimulation test: correlations with patients\u2019 auxological and metabolic parameters in a single Centre study","volume":"68","author":"Sodero","year":"2023","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2023.101532_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.691240","article-title":"Etiology and treatment of growth delay in Noonan syndrome","volume":"12","author":"Rodr\u00edguez","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0270","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11154-006-9021-1","article-title":"Noonan syndrome and related disorders: alterations in growth and puberty","volume":"7","author":"Noonan","year":"2006","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.ghir.2023.101532_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1011960","article-title":"Genetic conditions of short stature: a review of three classic examples","volume":"13","author":"Butler","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0280","first-page":"129","article-title":"Abnormal growth in Noonan syndrome: genetic and endocrine features and optimal treatment","volume":"70","author":"Padidela","year":"2008","journal-title":"Horm. Res."},{"key":"10.1016\/j.ghir.2023.101532_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.951331","article-title":"Inside the Noonan \u201cuniverse\u201d: literature review on growth, GH\/IGF axis and rhGH treatment: facts and concerns","volume":"13","author":"Stagi","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.ghir.2023.101532_bb0290","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/jcm11072034","article-title":"Growth, endocrine features, and growth hormone treatment in Noonan syndrome","volume":"11","author":"Dahlgren","year":"2022","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.ghir.2023.101532_bb0295","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.ghir.2023.101532_bb0300","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0305","first-page":"340","article-title":"Growth hormone replacement therapy in pediatric brain tumor survivors","volume":"74","author":"Sodero","year":"2022","journal-title":"Minerva Pediatr. (Torino)"},{"issue":"4","key":"10.1016\/j.ghir.2023.101532_bb0310","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ajmg.a.38108","article-title":"Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature","volume":"173","author":"Siegfried","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.ghir.2023.101532_bb0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12020-014-0327-6","article-title":"GH and the cardiovascular system: an update on a topic at heart","volume":"48","author":"Isgaard","year":"2015","journal-title":"Endocrine."},{"issue":"2","key":"10.1016\/j.ghir.2023.101532_bb0320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/JPEM.2002.15.2.175","article-title":"The relationship between clinical severity of Noonan\u2019s syndrome and growth, growth hormone (GH) secretion and response to GH treatment","volume":"15","author":"Noordam","year":"2002","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ghir.2023.101532_bb0325","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.ghir.2023.101532_bb0330","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2020.5199","article-title":"Association of childhood growth hormone treatment with long-term cardiovascular morbidity","volume":"175","author":"Tidblad","year":"2021","journal-title":"JAMA Pediatr."},{"issue":"3","key":"10.1016\/j.ghir.2023.101532_bb0335","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000371635","article-title":"The impact of growth hormone therapy on adult height in Noonan syndrome: a systematic review","volume":"83","author":"Giacomozzi","year":"2015","journal-title":"Horm. Res. Paediatr."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637423000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637423000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:52:49Z","timestamp":1761087169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637423000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":66,"alternative-id":["S1096637423000102"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2023.101532","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of growth hormone therapy in children with Noonan syndrome","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2023.101532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101532"}}